The procedure used for RNase H site-specific cleavage of ovalbumin mRNA was adapted from those previously described (Donis-Keller, 1979, Nucl. Acid. Res. 7: 179-192). Briefly, 5-10 μg mRNA from E.G7-OVA cells was suspended in 20 m HEPES-KOH, pH 8.0, 50 mM KCl, 4 mM $MgCL_2$, 1 mM DTT, 50 μg/ml BSA and 2 μM of either the oligodeoxynucleotide 5'-CAG TTT TTC AAA GTT GAT TAT ACT-3' (SEQ ID NO:1), which hybridizes to sequence in OVA mRNA that codes for the CTL epitope SIINFEKL (SEQ ID NO:3), or 5'-TCA TAT TAG TTG AAA CTT TTT GAC-3' (SEQ ID NO:2) (Oligos, Etc.), which serves as a negative control. The samples were heated to 50°C for 3 minutes followed by incubation at 37°C for 30 minutes. RNase H (Boehringer-Mannheim) was added at 10 U/ml, and digestion proceeded for 30 minutes at 37°C. RNA was recovered by phenol:choloroform and chloroform extraction, followed by isopropanol precipitation. RNA was pelleted by microcentrifugation, and the pellet was washed once with 70% ethanol. The pellet then was air-dried and resuspended in sterile water. Cleavage of OVA mRNA was confirmed by oligo dT primed reverse transcription of test and control samples, followed by PCR with OVA specific primers that flank the cleavage site. PCR with actin-specific primers was used to control between test and control samples.

Please replace the paragraph beginning at page 19, line 25, with the following rewritten paragraph:

The synthetic peptide encoding the CTL epitope in chicken ovalbumin OVA, aa 257-264 SIINFEKL (SEQ ID NO:3) ($H\text{-}2K^b$), was used for peptide pulsing. The peptide had unblocked (free) amino and carboxyl ends (Research Genetics, Birmingham, AL). Peptides were dissolved in serum-free IMDM and stored at -20°C.

Before the Figures, insert the Sequence Listing submitted herewith.

REMARKS

Favorable consideration of this application and entry of the foregoing amendments are respectfully requested.

In response to the Examiner's requirement for restriction, set forth in the Office Action dated August 30, 2002, in the above matter. Applicants elect, with traverse, the subject matter of Group IV (claims 19 and 20) for prosecution in this application.

The specification has been amended to make reference to sequence identifiers and to include the Sequence Listing submitted herewith on separate sheets. Entry of the